A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.

Mark Monane, Kim G Johnson,B Joy Snider,Raymond S Turner,Jonathan D Drake,Demetrius M Maraganore, James L Bicksel, Daniel H Jacobs,Julia L Ortega, Joni Henderson,Yan Jiang,Shuguang Huang,Justine Coppinger,Ilana Fogelman,Tim West,Joel B Braunstein

Annals of clinical and translational neurology（2023）

引用 1|浏览15

暂无评分

摘要

These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.

查看译文

关键词

brain amyloid,blood biomarker test,cognitive impairment,clinical evaluation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要